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independent components was used (FimQAPro). Dose-maps were 
compared to treatment plans using isodoses and gamma. Absolute film 
dose values were used with no re-normalisation of any data. Isolated 
source doses were compared to TG-43 source model values. The value 
and sensitivity of gamma for brachytherapy applications was assessed 
by multivariate analysis of area/position and calculation parameters. 
Eckert & Ziegler Bebig GmbH HDR multiSource treatment unit, with 
Co-60 source, and HDRplus treatment planning system (TPS) were 
used throughout. 
Results: Figure 1 shows dose maps from 2 films positioned adjacent to 
and bisecting the cervix applicator intrauterine (IU) channel, overlaid 
on TPS isodoses. Agreement in isodoses, 75 cGy to 2000 cGy, is 
generally within 1.0 mm. A comparison of the 2 symmetric films 
confirms sufficient reproducibility. Table 1 provides example gamma 
results for the cervix and shielded vaginal applicators. The passing 
rate in brachytherapy is sensitive to the defined interest region, in the 
cervix example ranging from 95% at typical HR-CTV to 100% at a 
bladder position, for 3% (local) / 2 mm criteria, evaluated over 9 cm2 
regions. The full-region, 144 cm2, passing rate was ~ 98%. 
The validity of the TG-43 general source model for individual supplied 
HDR sources was successfully verified. Gamma passing rates > 95% at 
3% (local) / 2 mm between 5 mm and 50 mm from the source. 
 
 
 
 
 
 
  
Conclusions: There is an absence of clinically-relevant QC for modern 
brachytherapy. We have presented a practical, robust method of 
advanced film dosimetry of treatment applicators, which is more 
closely aligned to clinical treatments than current QC. Planned and 
measured isodoses agreed closely, with high gamma passing rates. 
Film dosimetry is advocated to confirm validity of the general TG-43 
model for individual supplied sources. The use and sensitivity of 
gamma for brachytherapy must be carefully considered; we propose 
separate calculations in a number of clinically relevant regions. 
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Purpose/Objective: In permanent seed implant prostate 
brachytherapy the actual dose delivered to the patient may be less 
than that calculated by TG43-U1 due to inter-seed attenuation (ISA) 
and differences between prostate tissue composition and water. In 
this study the ISA effect is assessed using Monte Carlo (MC) simulation 
of clinical prostate treatment plans. 
Materials and Methods: Simulations of ultrasound based pre-plans and 
CT based post-plans were performed for 30 patients treated with 6711 
seeds, the mean activity used was 0.44U. MC simulation results were 
compared to TG43-U1 using DVH parameters for the prostate, urethra, 
rectum and the volume enclosed by the 100% isodose. Use of gamma 
index values to compare MC simulation results and TG43-U1 was 
investigated. Areas of the prostate where ISA caused dose to drop 
below 100% of prescription dose were analysed. Sector analysis of ISA 
effects was performed dividing the prostate into apex, mid-gland and 
base segments, with each segment divided into anterior, posterior, 
left and right quadrants. 
Results: For CT post-plans, the mean ISA effect was to reduce 
prostate D90 by 4.2Gy (3%), prostate V100 by 0.5cc (1.4%), urethra 
D10 by 11.3Gy (4.4%), rectal D2cc by 5.5Gy (4.6%) and the 100% 
isodose volume by 2.3cc. For ultrasound pre-plans the mean ISA effect 
was smaller, reducing prostate D90 by 2.2% and the 100% isodose 
volume by 1.5cc. For distance to agreement 2mm and dose difference 
3% the number of points in the prostate with gamma <=1 was 95.3% 
for CT based post-plans and 97.8% for US based pre-plans. The number 
of points with gamma <=1 correlated strongly with ISA effect on DVH 
parameters (p<0.01). Sector analysis showed that in CT post-plans the 
majority of points where ISA causes prostate dose to fall below 100% 
are near the prostate base however this is not true for ultrasound pre-
plans as these have more uniform coverage and seed spacing. 
Conclusions: ISA causes the delivered dose in prostate seed implant 
brachytherapy to be lower than the dose calculated by TG43-U1. 
Because of differences in seed positions between pre-plan and post-
plan, the effect of ISA on the post-plan could not necessarily be 
predicted from the pre-plan. For this group of patients ISA had most 
impact at the prostate base, an area which is often underdosed even 
excluded any effects of ISA.  
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Purpose/Objective: It is well-known that tissue heterogeneities and 
calcifications have significant influence on low energy brachytherapy 
such as prostate permanent I-125 implants. The aim of this work is to 
study the application of a simplified analytic algorithm that could be 
compatible with commercial Treatment Planning System (TPS) based 
on TG-43. The algorithm, based on the classic equivalent path length 
method, has been tested with Monte Carlo (MC) computations using 
Penelope2009. 
Materials and Methods: The analytical model scales the distance from 
the seed to the calculation point according to the electronic density 
of the medium relative to water. Then the dose is obtained from TG-
43 consensus data stored on a TPS but with the radial dose function 
obtained for the scaled distance keeping the anisotropy function 
unaltered. A voxelized phantom obtained from real cases has been 
used. This case was selected as a benchmark because the patient 
presented a significant proportion of calcifications inside the prostate. 
After this step a comparison between MC and the algorithm was 
performed.  
Results: The results given by the algorithm show a remarkable 
agreement with the complete Monte Carlo simulations taking into 
account the calcifications in the aforementioned real case. Several 
other realistic geometries and compositions of the calcification have 
been checked successfully. In the figure below two different imaging 
planes can be observed (black arrows in the insets). Blue lines stands 
for TG-43 based results, green lines for the algorithm, and red ones 
for MC simulations. More overdose rate times the distance squared 
and divided by air-kerma strength is given. 
 
